Celltrion: "Jimpentra Achieves Record-High Weekly Prescriptions in the U.S."

"Impact of Expanded Marketing and Reimbursement Begins in Earnest"

Celltrion's infliximab subcutaneous (SC) injection therapy, Jimpentra, has recorded its highest weekly prescription volume in the United States since its launch. The increase in prescriptions is attributed to strengthened local marketing efforts and expanded insurance reimbursement coverage.

On January 28, Celltrion announced that Jimpentra achieved a record-high weekly prescription volume (TRx) in the second week of January 2026. This represents a 27% increase compared to the same period in the previous month and a 352% increase year-on-year. Jimpentra was launched in the U.S. in March 2024.

Jimpentra Product Advertisement Image. Celltrion

The company explained that expanding both online and offline advertising in the U.S. was a key factor behind the rise in prescriptions. The strategy involved running TV and YouTube ads targeting the general public, alongside in-hospital advertisements aimed at healthcare professionals and patients. This approach, which simultaneously raised disease awareness and targeted actual prescription environments, has been evaluated as highly effective.

Rapidly securing a foundation for insurance reimbursement also contributed to the increase in prescriptions. Celltrion's U.S. subsidiary negotiated with multiple insurance providers, including the three largest pharmacy benefit managers (PBMs), securing reimbursement coverage for over 90% of the market. As patients' out-of-pocket costs decreased, prescription barriers for healthcare professionals were also lowered.

Recently, Jimpentra was listed as a preferred drug in the formulary of Evernorth Health Services, a subsidiary of the Cigna Group. As a result, Cigna-affiliated insurance policyholders can now receive Jimpentra prescriptions without additional administrative procedures. The company expects this to provide further momentum for prescription growth in the future.

Celltrion anticipates that Jimpentra's U.S. sales growth will accelerate starting this year. The company plans to increase marketing investments while highlighting the therapeutic efficacy of infliximab and the convenience of the SC formulation based on clinical data. The strategy is to actively promote the advantages of Jimpentra for maintenance therapy in inflammatory bowel diseases such as ulcerative colitis and Crohn's disease.

A Celltrion representative stated, "Since the beginning of the new year, Jimpentra's prescription volume has increased more than 4.5 times year-on-year, confirming that our local marketing activities and expanded reimbursement coverage are translating into actual prescriptions. We plan to carry out even more aggressive media advertising and product promotion activities going forward."

This content was produced with the assistance of AI translation services.